GLP1R and obesity due to melanocortin 4 receptor deficiency: The use of GLP-1-based treatment has expanded within recent years and has provided significant support to reducing the effects of not only obesity and diabetes, but also diseases that affect the cardiovascular system, renal function, liver function, and even sleep (specifically obstructive sleep apnea) [70,101,102].